IFT172

Across TCGA pan-cancer cohorts, IFT172 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated IFT172 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IFT172 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IFT172 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

HNSC, UCEC, and LUAD are the cancer types where IFT172 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.341	0.690	.001	44	view →
UCEC	DFS	Median	All	0.965	0.825	.011	30	view →
LUAD	OS	Median	All	0.318	0.686	<.001	28	view →
LIHC	DFS	Median	All	0.081	0.527	.012	15	view →
BLCA	OS	Median	III,IV	1.000	0.380	.025	7	view →
STAD	DFS	Median	II,III,IV	1.000	0.373	.012	6	view →
SCLC	DFS	Median	All	0.274	0.815	.013	6	view →
MESO	OS	Median	All	0.169	0.556	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

IFT172–HNSC (OS)

Open the HNSC breakdown →